Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma

Systematic Functional Annotation of Somatic Mutations in Cancer

(2018) Patrick Kwok-Shing Ng et al.   CANCER CELL

Mutations in the signal transducer and activator of transcription family of genes in cancer

(2018) Nahid Shahmarvand et al.   CANCER SCIENCE

STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC

(2017) L.L. Bu et al.   JOURNAL OF DENTAL RESEARCH

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

(2017) V Atsaves et al.   LEUKEMIA

Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera

(2017) T Tsuruta-Kishino et al.   ONCOGENE

Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type

(2016) Jae-Cheol Jo et al.   ANNALS OF HEMATOLOGY

Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas

(2016) L. C. Chong et al.   BLOOD

STAT3 mutations are not sufficient to induce large granular lymphocytic leukaemia in mice

(2016) Avik Dutta et al.   BRITISH JOURNAL OF HAEMATOLOGY

FrequentBCORaberrations in extranodal NK/T-Cell lymphoma, nasal type

(2016) Akito Dobashi et al.   GENES CHROMOSOMES & CANCER

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma

(2016) M-L Nairismägi et al.   LEUKEMIA

Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas

(2016) A Nicolae et al.   LEUKEMIA

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

UniProt: the universal protein knowledgebase

(2016)   NUCLEIC ACIDS RESEARCH

Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis

(2016) Wook Youn Kim et al.   VIRCHOWS ARCHIV

Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2

(2016) Zhuo Ren et al.   Cell Death & Disease

Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity

(2016) Wen Fong Ooi et al.   Nature Communications

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma

(2016) Stefan Ehrentraut et al.   Oncotarget

GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells

(2016) Mobashar Hussain Urf Turabe Fazil et al.   Scientific Reports

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

(2015) Ramona Crescenzo et al.   CANCER CELL

Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma

(2015) C. Perez et al.   HAEMATOLOGICA

On Human Disease-Causing Amino Acid Variants: Statistical Study of Sequence and Structural Patterns

(2015) Marharyta Petukh et al.   HUMAN MUTATION

Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation

(2015) Olaf Merkel et al.   JOURNAL OF PATHOLOGY

Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia

(2015) E Andersson et al.   LEUKEMIA

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

(2015) Yu Fujita et al.   MOLECULAR THERAPY

Non-coding recurrent mutations in chronic lymphocytic leukaemia

(2015) Xose S. Puente et al.   NATURE

Genomic landscape of cutaneous T cell lymphoma

(2015) Jaehyuk Choi et al.   NATURE GENETICS

Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma

(2015) Lu Jiang et al.   NATURE GENETICS

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK–STAT pathway in Sézary syndrome

(2015) Mark J. Kiel et al.   Nature Communications

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

(2015) Can Küçük et al.   Nature Communications

Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type

(2015) Seungbok Lee et al.   Oncotarget

Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma

(2015) C. Perez et al.   HAEMATOLOGICA

Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses

(2015) Wei-Bei Wang et al.   Stem Cell Reports

SOCS1 Mutation Subtypes Predict Divergent Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients

(2015) Birgit Schif et al.   Oncotarget

Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations

(2014) J. D. Milner et al.   BLOOD

Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis

(2014) J H Schatz et al.   LEUKEMIA

Somatic RHOA mutation in angioimmunoblastic T cell lymphoma

(2014) Mamiko Sakata-Yanagimoto et al.   NATURE GENETICS

Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms

(2014) Raajit Rampal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma

(2014) LIJUAN HAN et al.   Oncology Letters

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma

(2013) Z. Kan et al.   GENOME RESEARCH

STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model

(2013) L. Couronne et al.   HAEMATOLOGICA

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma

(2013) A Bouchekioua et al.   LEUKEMIA

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas

(2012) G. Vasmatzis et al.   BLOOD

SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia

(2012) Hanna L.M. Koskela et al.   NEW ENGLAND JOURNAL OF MEDICINE

Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma

(2012) Ghee Chong Koo et al.   Cancer Discovery

Stat3 and MMP7 Contribute to Pancreatic Ductal Adenocarcinoma Initiation and Progression

(2011) Akihisa Fukuda et al.   CANCER CELL

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

(2011) Marina Lesina et al.   CANCER CELL

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas

(2011) Camilla Pilati et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Epstein-Barr Virus LMP1 Activates EGFR, STAT3, and ERK through Effects on PKC 

(2011) C.-P. Kung et al.   JOURNAL OF VIROLOGY

Yin-Yang of costimulation: crucial controls of immune tolerance and function

(2009) Roza I. Nurieva et al.   IMMUNOLOGICAL REVIEWS

STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma

(2009) P Coppo et al.   LEUKEMIA

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

Activating mutations in human acute megakaryoblastic leukemia

(2008) S. Malinge et al.   BLOOD

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY

An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing

(2008) Susan Li Er Loong et al.   LEUKEMIA & LYMPHOMA

Signal Transducer and Activator of Transcription 3 Is Required for Hypoxia-Inducible Factor-1  RNA Expression in Both Tumor Cells and Tumor-Associated Myeloid Cells

(2008) G. Niu et al.   MOLECULAR CANCER RESEARCH

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA